Stocks and Investing Stocks and Investing
Wed, August 28, 2024

Gregory Renza Reiterated (VRDN) at Buy and Held Target at $35 on, Aug 28th, 2024


Published on 2024-10-28 13:56:18 - WOPRAI, Gregory Renza
  Print publication without navigation


Gregory Renza of RBC Capital, Reiterated "Viridian Therapeutics, Inc." (VRDN) at Buy and Held Target at $35 on, Aug 28th, 2024.

Gregory has made no other calls on VRDN in the last 4 months.



There are 8 other peers that have a rating on VRDN. Out of the 8 peers that are also analyzing VRDN, 2 agree with Gregory's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Higgins of "Ladenburg Thalmann" Downgraded from Strong Buy to Hold on, Thursday, May 9th, 2024
  • Kalpit Patel of "B. Riley Securities" Downgraded from Strong Buy to Hold and Decreased Target to $20 on, Thursday, May 9th, 2024


These are the ratings of the 6 analyists that currently disagree with Gregory


  • Douglas Tsao of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $27 on, Thursday, August 15th, 2024
  • Leland Gershell of "Oppenheimer" Reiterated at Buy with Decreased Target to $28 on, Monday, August 12th, 2024
  • Laura Chico of "Wedbush" Reiterated at Buy and Held Target at $42 on, Monday, July 29th, 2024
  • Andy Chen of "Wolfe Research" Initiated at Buy on, Tuesday, June 11th, 2024
  • Serge Belanger of "Needham" Reiterated at Strong Buy and Held Target at $30 on, Tuesday, June 11th, 2024
  • Richard Law of "Goldman Sachs" Initiated at Strong Buy and Held Target at $23 on, Thursday, June 6th, 2024
Contributing Sources